Oramed Pharmaceuticals Reports Director/Officer Changes & Shareholder Votes

TL;DR

Oramed's leadership is changing, and they're holding a shareholder vote.

AI Summary

Oramed Pharmaceuticals Inc. filed an 8-K on August 21, 2025, reporting on events that occurred on August 19, 2025. The filing indicates changes related to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. It also covers the submission of matters to a vote of security holders.

Why It Matters

This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational decisions.

Risk Assessment

Risk Level: medium — Changes in directors and officers, along with shareholder votes, can indicate internal shifts or strategic realignments that may carry inherent business risks.

Key Players & Entities

• ORAMED PHARMACEUTICALS INC. (company) — Registrant
• August 19, 2025 (date) — Earliest event date
• August 21, 2025 (date) — Filing date

FAQ

Key Financial Figures

• $0.012 — ch registered Common Stock, par value $0.012 ORMP The Nasdaq Capital Market, Te

Filing Documents

• ea0254007-8k_oramed.htm (8-K) — 46KB
• 0001213900-25-079361.txt ( ) — 208KB
• ormp-20250819.xsd (EX-101.SCH) — 3KB
• ormp-20250819_lab.xml (EX-101.LAB) — 33KB
• ormp-20250819_pre.xml (EX-101.PRE) — 22KB
• ea0254007-8k_oramed_htm.xml (XML) — 4KB

02. Departure of Directors or Certain

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 19, 2025, Oramed Pharmaceuticals Inc. (the "Company") held its 2025 Annual Meeting of Stockholders. At the 2025 Annual Meeting of Stockholders, the Company's stockholders approved an amendment of the Company's Amended and Restated 2019 Stock Incentive Plan, as amended (the " Amended and Restated 2019 Plan"), to increase the aggregate number of shares of common stock, par value $0.012 per share, of the Company ("Common Stock") authorized for issuance under the Amended and Restated 2019 Plan by 2,000,000 shares of Common Stock to 9,500,000 shares of Common Stock. The amendment to the Amended and Restated 2019 Plan previously had been approved, subject to stockholder approval, by the Company's Board of Directors. The Company's officers and directors are among the persons eligible to receive awards under the Amended and Restated 2019 Plan in accordance with the terms and conditions thereunder. A detailed summary of the amendment to the Amended and Restated 2019 Plan is set forth in the Company's Definitive Proxy Statement on Schedule 14A for the 2025 Annual Meeting of Stockholders filed with the Securities and Exchange Commission on July 16, 2025 (the "Proxy The full text of the amendment to the Amended and Restated 2019 Plan is attached as Appendix A to the Proxy Statement and incorporated herein by reference.

07. Submission of Matters to a Vote

Item 5.07. Submission of Matters to a Vote of Security Holders. On August 19, 2025, the Company held its 2025 Annual Meeting of Stockholders. The final voting results at the 2025 Annual Meeting of Stockholders are set forth below. Proposal No. 1 - Re-election of Directors. The stockholders re-elected the following directors of the Company to hold office until the next annual meeting of stockholders and until their respective successors shall be elected and qualified or until their earlier resignation or removal. The votes were as follows: Director Name For Against Abstain Broker Non-Votes Dr. Daniel Aghion 13,045,437 163,976 1,192,536 6,384,104 Dr. Miriam Kidron 13,031,039 1,333,997 36,913 6,384,104 Nadav Kidron 12,989,716 1,375,014 37,219 6,384,104 Dr. Arie Mayer 12,994,256 215,059 1,192,634 6,384,104 Yehuda Reznick 13,036,242 172,951 1,192,756 6,384,104 Leonard Sank 12,888,223 320,710 1,193,016 6,384,104 Benjamin Shapiro 12,456,964 753,720 1,191,265 6,384,104 1 Proposal No. 2 – Ratification of Independent Registered Public Accounting Firm for the 2025 Fiscal Year. The stockholders ratified the appointment of Kesselman & Kesselman, certified public accountants in Israel, a member of PricewaterhouseCoopers International Limited, as the independent registered public accounting firm of the Company for the 2025 fiscal year. The votes were as follows: For Against Abstain Broker Non-Votes 19,408,725 1,359,336 17,992 0 Proposal No. 3 – Approval of an Amendment to the Company's Amended and Restated 2019 Stock Incentive Plan. The stockholders approved an amendment to the Company's Amended and Restated 2019 Stock Incentive Plan. The votes were as follows: For Against Abstain Broker Non-Votes 12,254,197 2,106,100 41,652 6,384,104 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORAMED PHARMACEUTICALS INC. By: /s/ Nadav Kidron Name: Nadav Kidron Title: President and CEO August 21, 2025 3

View Full Filing

View this 8-K filing on SEC EDGAR